https://invesbrain.com/revive-therapeutics-may-seek-fda-approval-to-amend-phase-3-endpoints-in-bucillamine-trial-to-a-symptoms-focus/
Revive Therapeutics May Seek FDA Approval To Amend Phase 3 Endpoints In Bucillamine Trial To A Symptoms Focus